The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Personalized Medicine and Epigenomics Market Research Report 2025
Synopsis
The global Personalized Medicine and Epigenomics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Personalized Medicine and Epigenomics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Personalized Medicine and Epigenomics.
Report Scope
The Personalized Medicine and Epigenomics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Personalized Medicine and Epigenomics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Personalized Medicine and Epigenomics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Laboratories
Affymetrix
Agilent Technologies
Astellas Pharmaceuticals
BAYER AG
Bio Vision
Celgene Corp.
Emd Millipore
Epigenomics AG
Epigentex
Envivo Pharmaceuticals (Forum Pharmaceutricals)
Gilead Sciences
Glaxosmithkline
Illumina Inc.
Johnson & Johnson
Karus Therapeutics Limited
Laboratory Corp. Of America Holdings
LES Laboratoires Servier
Merck
Naturewise Biotech & Medicals Corp.
Novartis Pharma AG
Oncolys Biopharma Inc.
Orchid Chemicals & Pharmaceuticals Limited
Progen Pharmaceuticals Limited
Quest Diagnostics
Roche Holding AG
Rubicon Genomics
Takeda Pharmaceutical Company Limited
Segment by Type
Reagents
Kits
Instruments
Enzymes
Services
Segment by Application
Oncology
Non-Oncology
Cancer Drug Technology
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Personalized Medicine and Epigenomics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Personalized Medicine and Epigenomics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Personalized Medicine and Epigenomics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Personalized Medicine and Epigenomics.
Report Scope
The Personalized Medicine and Epigenomics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Personalized Medicine and Epigenomics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Personalized Medicine and Epigenomics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Laboratories
Affymetrix
Agilent Technologies
Astellas Pharmaceuticals
BAYER AG
Bio Vision
Celgene Corp.
Emd Millipore
Epigenomics AG
Epigentex
Envivo Pharmaceuticals (Forum Pharmaceutricals)
Gilead Sciences
Glaxosmithkline
Illumina Inc.
Johnson & Johnson
Karus Therapeutics Limited
Laboratory Corp. Of America Holdings
LES Laboratoires Servier
Merck
Naturewise Biotech & Medicals Corp.
Novartis Pharma AG
Oncolys Biopharma Inc.
Orchid Chemicals & Pharmaceuticals Limited
Progen Pharmaceuticals Limited
Quest Diagnostics
Roche Holding AG
Rubicon Genomics
Takeda Pharmaceutical Company Limited
Segment by Type
Reagents
Kits
Instruments
Enzymes
Services
Segment by Application
Oncology
Non-Oncology
Cancer Drug Technology
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Personalized Medicine and Epigenomics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Personalized Medicine and Epigenomics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Reagents
1.2.3 Kits
1.2.4 Instruments
1.2.5 Enzymes
1.2.6 Services
1.3 Market by Application
1.3.1 Global Personalized Medicine and Epigenomics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oncology
1.3.3 Non-Oncology
1.3.4 Cancer Drug Technology
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Personalized Medicine and Epigenomics Market Perspective (2019-2030)
2.2 Personalized Medicine and Epigenomics Growth Trends by Region
2.2.1 Global Personalized Medicine and Epigenomics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Personalized Medicine and Epigenomics Historic Market Size by Region (2019-2024)
2.2.3 Personalized Medicine and Epigenomics Forecasted Market Size by Region (2025-2030)
2.3 Personalized Medicine and Epigenomics Market Dynamics
2.3.1 Personalized Medicine and Epigenomics Industry Trends
2.3.2 Personalized Medicine and Epigenomics Market Drivers
2.3.3 Personalized Medicine and Epigenomics Market Challenges
2.3.4 Personalized Medicine and Epigenomics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Personalized Medicine and Epigenomics Players by Revenue
3.1.1 Global Top Personalized Medicine and Epigenomics Players by Revenue (2019-2024)
3.1.2 Global Personalized Medicine and Epigenomics Revenue Market Share by Players (2019-2024)
3.2 Global Personalized Medicine and Epigenomics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Personalized Medicine and Epigenomics Revenue
3.4 Global Personalized Medicine and Epigenomics Market Concentration Ratio
3.4.1 Global Personalized Medicine and Epigenomics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Personalized Medicine and Epigenomics Revenue in 2023
3.5 Personalized Medicine and Epigenomics Key Players Head office and Area Served
3.6 Key Players Personalized Medicine and Epigenomics Product Solution and Service
3.7 Date of Enter into Personalized Medicine and Epigenomics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Personalized Medicine and Epigenomics Breakdown Data by Type
4.1 Global Personalized Medicine and Epigenomics Historic Market Size by Type (2019-2024)
4.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Type (2025-2030)
5 Personalized Medicine and Epigenomics Breakdown Data by Application
5.1 Global Personalized Medicine and Epigenomics Historic Market Size by Application (2019-2024)
5.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Personalized Medicine and Epigenomics Market Size (2019-2030)
6.2 North America Personalized Medicine and Epigenomics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Personalized Medicine and Epigenomics Market Size by Country (2019-2024)
6.4 North America Personalized Medicine and Epigenomics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Personalized Medicine and Epigenomics Market Size (2019-2030)
7.2 Europe Personalized Medicine and Epigenomics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Personalized Medicine and Epigenomics Market Size by Country (2019-2024)
7.4 Europe Personalized Medicine and Epigenomics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Personalized Medicine and Epigenomics Market Size (2019-2030)
8.2 Asia-Pacific Personalized Medicine and Epigenomics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region (2019-2024)
8.4 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Personalized Medicine and Epigenomics Market Size (2019-2030)
9.2 Latin America Personalized Medicine and Epigenomics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Personalized Medicine and Epigenomics Market Size by Country (2019-2024)
9.4 Latin America Personalized Medicine and Epigenomics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Personalized Medicine and Epigenomics Market Size (2019-2030)
10.2 Middle East & Africa Personalized Medicine and Epigenomics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2019-2024)
10.4 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Personalized Medicine and Epigenomics Introduction
11.1.4 Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.1.5 Abbott Laboratories Recent Development
11.2 Affymetrix
11.2.1 Affymetrix Company Detail
11.2.2 Affymetrix Business Overview
11.2.3 Affymetrix Personalized Medicine and Epigenomics Introduction
11.2.4 Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.2.5 Affymetrix Recent Development
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Detail
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Personalized Medicine and Epigenomics Introduction
11.3.4 Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.3.5 Agilent Technologies Recent Development
11.4 Astellas Pharmaceuticals
11.4.1 Astellas Pharmaceuticals Company Detail
11.4.2 Astellas Pharmaceuticals Business Overview
11.4.3 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Introduction
11.4.4 Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.4.5 Astellas Pharmaceuticals Recent Development
11.5 BAYER AG
11.5.1 BAYER AG Company Detail
11.5.2 BAYER AG Business Overview
11.5.3 BAYER AG Personalized Medicine and Epigenomics Introduction
11.5.4 BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.5.5 BAYER AG Recent Development
11.6 Bio Vision
11.6.1 Bio Vision Company Detail
11.6.2 Bio Vision Business Overview
11.6.3 Bio Vision Personalized Medicine and Epigenomics Introduction
11.6.4 Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.6.5 Bio Vision Recent Development
11.7 Celgene Corp.
11.7.1 Celgene Corp. Company Detail
11.7.2 Celgene Corp. Business Overview
11.7.3 Celgene Corp. Personalized Medicine and Epigenomics Introduction
11.7.4 Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.7.5 Celgene Corp. Recent Development
11.8 Emd Millipore
11.8.1 Emd Millipore Company Detail
11.8.2 Emd Millipore Business Overview
11.8.3 Emd Millipore Personalized Medicine and Epigenomics Introduction
11.8.4 Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.8.5 Emd Millipore Recent Development
11.9 Epigenomics AG
11.9.1 Epigenomics AG Company Detail
11.9.2 Epigenomics AG Business Overview
11.9.3 Epigenomics AG Personalized Medicine and Epigenomics Introduction
11.9.4 Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.9.5 Epigenomics AG Recent Development
11.10 Epigentex
11.10.1 Epigentex Company Detail
11.10.2 Epigentex Business Overview
11.10.3 Epigentex Personalized Medicine and Epigenomics Introduction
11.10.4 Epigentex Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.10.5 Epigentex Recent Development
11.11 Envivo Pharmaceuticals (Forum Pharmaceutricals)
11.11.1 Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Detail
11.11.2 Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview
11.11.3 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Introduction
11.11.4 Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.11.5 Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Development
11.12 Gilead Sciences
11.12.1 Gilead Sciences Company Detail
11.12.2 Gilead Sciences Business Overview
11.12.3 Gilead Sciences Personalized Medicine and Epigenomics Introduction
11.12.4 Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.12.5 Gilead Sciences Recent Development
11.13 Glaxosmithkline
11.13.1 Glaxosmithkline Company Detail
11.13.2 Glaxosmithkline Business Overview
11.13.3 Glaxosmithkline Personalized Medicine and Epigenomics Introduction
11.13.4 Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.13.5 Glaxosmithkline Recent Development
11.14 Illumina Inc.
11.14.1 Illumina Inc. Company Detail
11.14.2 Illumina Inc. Business Overview
11.14.3 Illumina Inc. Personalized Medicine and Epigenomics Introduction
11.14.4 Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.14.5 Illumina Inc. Recent Development
11.15 Johnson & Johnson
11.15.1 Johnson & Johnson Company Detail
11.15.2 Johnson & Johnson Business Overview
11.15.3 Johnson & Johnson Personalized Medicine and Epigenomics Introduction
11.15.4 Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.15.5 Johnson & Johnson Recent Development
11.16 Karus Therapeutics Limited
11.16.1 Karus Therapeutics Limited Company Detail
11.16.2 Karus Therapeutics Limited Business Overview
11.16.3 Karus Therapeutics Limited Personalized Medicine and Epigenomics Introduction
11.16.4 Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.16.5 Karus Therapeutics Limited Recent Development
11.17 Laboratory Corp. Of America Holdings
11.17.1 Laboratory Corp. Of America Holdings Company Detail
11.17.2 Laboratory Corp. Of America Holdings Business Overview
11.17.3 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Introduction
11.17.4 Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.17.5 Laboratory Corp. Of America Holdings Recent Development
11.18 LES Laboratoires Servier
11.18.1 LES Laboratoires Servier Company Detail
11.18.2 LES Laboratoires Servier Business Overview
11.18.3 LES Laboratoires Servier Personalized Medicine and Epigenomics Introduction
11.18.4 LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.18.5 LES Laboratoires Servier Recent Development
11.19 Merck
11.19.1 Merck Company Detail
11.19.2 Merck Business Overview
11.19.3 Merck Personalized Medicine and Epigenomics Introduction
11.19.4 Merck Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.19.5 Merck Recent Development
11.20 Naturewise Biotech & Medicals Corp.
11.20.1 Naturewise Biotech & Medicals Corp. Company Detail
11.20.2 Naturewise Biotech & Medicals Corp. Business Overview
11.20.3 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Introduction
11.20.4 Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.20.5 Naturewise Biotech & Medicals Corp. Recent Development
11.21 Novartis Pharma AG
11.21.1 Novartis Pharma AG Company Detail
11.21.2 Novartis Pharma AG Business Overview
11.21.3 Novartis Pharma AG Personalized Medicine and Epigenomics Introduction
11.21.4 Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.21.5 Novartis Pharma AG Recent Development
11.22 Oncolys Biopharma Inc.
11.22.1 Oncolys Biopharma Inc. Company Detail
11.22.2 Oncolys Biopharma Inc. Business Overview
11.22.3 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Introduction
11.22.4 Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.22.5 Oncolys Biopharma Inc. Recent Development
11.23 Orchid Chemicals & Pharmaceuticals Limited
11.23.1 Orchid Chemicals & Pharmaceuticals Limited Company Detail
11.23.2 Orchid Chemicals & Pharmaceuticals Limited Business Overview
11.23.3 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
11.23.4 Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.23.5 Orchid Chemicals & Pharmaceuticals Limited Recent Development
11.24 Progen Pharmaceuticals Limited
11.24.1 Progen Pharmaceuticals Limited Company Detail
11.24.2 Progen Pharmaceuticals Limited Business Overview
11.24.3 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
11.24.4 Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.24.5 Progen Pharmaceuticals Limited Recent Development
11.25 Quest Diagnostics
11.25.1 Quest Diagnostics Company Detail
11.25.2 Quest Diagnostics Business Overview
11.25.3 Quest Diagnostics Personalized Medicine and Epigenomics Introduction
11.25.4 Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.25.5 Quest Diagnostics Recent Development
11.26 Roche Holding AG
11.26.1 Roche Holding AG Company Detail
11.26.2 Roche Holding AG Business Overview
11.26.3 Roche Holding AG Personalized Medicine and Epigenomics Introduction
11.26.4 Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.26.5 Roche Holding AG Recent Development
11.27 Rubicon Genomics
11.27.1 Rubicon Genomics Company Detail
11.27.2 Rubicon Genomics Business Overview
11.27.3 Rubicon Genomics Personalized Medicine and Epigenomics Introduction
11.27.4 Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.27.5 Rubicon Genomics Recent Development
11.28 Takeda Pharmaceutical Company Limited
11.28.1 Takeda Pharmaceutical Company Limited Company Detail
11.28.2 Takeda Pharmaceutical Company Limited Business Overview
11.28.3 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Introduction
11.28.4 Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2019-2024)
11.28.5 Takeda Pharmaceutical Company Limited Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Industrial Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
